过敏性疾病诊疗模式的演变:2007–2016年医疗保险数据分析
该分析基于2007–2016年美国CMS数据,探讨过敏诊疗趋势的变化。结果显示过敏检测增长49.7%,超过免疫治疗注射的19.6%增长,且检测与治疗比存在地域差异。耳鼻咽喉科医生承担31.2%的免疫治疗,过敏科医生占51.6%,舌下免疫治疗计费极少。
要点
- 过敏检测增长快于免疫治疗注射,检测与治疗比存在地域差异。
- 2016年免疫治疗主要由过敏科医生(51.6%)和耳鼻咽喉科医生(31.2%)实施。
- 舌下免疫治疗在医保人群中计费极少,不占重要地位。
核心结论
- 近年来医生对过敏性疾病的检查更积极,检测增长超过免疫治疗增长。
- 检测与免疫治疗比存在巨大地域差异。
- 耳鼻咽喉科在免疫治疗中角色稳定,过敏科管理多数患者,强调跨学科合作。
- 舌下免疫治疗在该人群中作用不显著。
研究设计与样本
- 分析2007–2016年CMS数据中过敏免疫治疗注射(CPT 95115、95117)和检测(CPT 95004、95024)的时间趋势。
- 分析地理趋势及实施免疫治疗的执业者。
- 获取未列明过敏/免疫服务(CPT 95199,包括SLIT)的计费数据。
主要发现
- 检测增长49.7%,免疫治疗给药增长19.6%。
- 检测与免疫治疗比最高在南部(0.35),最低在东北部(0.18)。
- 未列明过敏服务计费最高为594次,而每年皮下免疫治疗(SCIT)总量达数百万次。
- 2016年免疫治疗由过敏科/免疫科医生(51.6%)和耳鼻咽喉科医生(31.2%)实施,自2012年以来趋势稳定。
临床怎么用
- 耳鼻咽喉科医生应关注过敏检测与免疫治疗的地域差异,合理评估患者。
- 鉴于过敏科医生管理多数免疫治疗患者,耳鼻咽喉科应加强跨学科合作。
- 舌下免疫治疗在医保人群中应用极少,临床决策需考虑此现实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This analysis explores the increasing heterogeneity of trends in allergy management under the premise that the practice of allergy has undergone significant changes in national economics, healthcare delivery, and treatment options from 2007 to 2016. METHODS: Centers for Medicare and Medicaid Services (CMS) data were obtained for: (1) temporal trends in allergy immunotherapy injection (Current Procedural Terminology [CPT] codes 95115, 95117) and testing (CPT 95004, 95024) from 2007 to 2016; (2) geographic trends; and (3) practitioners administering immunotherapy. Although there are no sublingual immunotherapy (SLIT) CPT codes, billing for unlisted allergy/immunologic services (CPT 95199) were obtained. RESULTS: Since 2007, there were 99.5 million allergy tests and 33.5 million immunotherapy injections billed to Medicare beneficiaries. Increases in testing have outpaced rising immunotherapy administration (49.7% vs 19.6% increase). Significant regional variation in testing rates was noted, with the greatest ratio of testing to immunotherapy in the South (0.35) and smallest ratio in the Northeast (0.18). The maximum unlisted allergy services billed was 594 (of which includes SLIT), compared to annual subcutaneous immunotherapy (SCIT) totals in the millions. The majority of immunotherapy in 2016 was administered by allergists/immunologists (51.6%) followed by otolaryngologists (31.2%), trends that have remained consistent since 2012. CONCLUSION: Physicians have been more aggressive in the workup of allergy-mediated disorders in recent years. Although differences in allergen load exist, there is tremendous geographic variation in the ratio of testing to immunotherapy. While the role otolaryngologists play in immunotherapy remains stable, allergists manage the majority of patients, reinforcing the importance of interdisciplinary cooperation and outreach. SLIT does not appear to play a significant role in this population.
引用
- Arianpour K, Svider PF, Yuhan B, et al. Evolving patterns in the diagnosis and management of allergy-mediated disorders. Int Forum Allergy Rhinol. 2018. PMID: 29782070. doi:10.1002/alr.22111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。